Why IsoRay (ISR) Stock Is Surging Today

NEW YORK (TheStreet) -- IsoRay (ISR) rose Monday after the medical technology company announced it had received final approval from the State of Washington Department of Health to manufacture its Liquid Cesium-131, or Cesitrex.

The U.S. Food and Drug Administration recently approved Liquid Cesium-131 to use with GliaSite balloon catheters to treat metastatic and glioblastoma brain cancers.

"Management believes this combination will offer a number of advantages in treating these debilitating brain cancers," the company said in a statement. "Liquid Cesium-131 eliminates the need for a thyroid block as required with Iodine-125, is safer for the patient and staff, and if a spill were to occur, it is an easier cleanup than with other isotopes."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 10.87% to $2.55 at 11:02 a.m.

ISR Chart

ISR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Insider Trading Alert - STRP, ISR And TCRD Traded By Insiders

Insider Trading Alert - STRP, ISR And TCRD Traded By Insiders

Insider Trading Alert - ISR, AAT And FB Traded By Insiders

Insider Trading Alert - ISR, AAT And FB Traded By Insiders

Insider Trading Alert - ISR, SIX And SUMR Traded By Insiders

Insider Trading Alert - ISR, SIX And SUMR Traded By Insiders

Strong On High Volume: IsoRay (ISR)

Strong On High Volume: IsoRay (ISR)

Trade-Ideas: IsoRay (ISR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: IsoRay (ISR) Is Today's "Dead Cat Bounce" Stock